Menu

Sequencing Genomes in the ICU Improves Outcomes

A handful of infants in a neonatal intensive care unit who were diagnosed with rare diseases using whole-genome sequencing had shorter hospital stays and better health outcomes, researchers find.

Oct 19, 2017
Bob Grant

WIKIMEDIA, BRIAN HALLChildren born with congenital abnormalities have a tough go at the beginnings of their lives. They can spend days, weeks, or months in neonatal intensive care units (NICU), hooked up to ventilators, fed through tubes, and regularly prodded and monitored to collect biological data. Some never make it out of the hospital. The ones who do can be saddled with poorly diagnosed health problems for the rest of their lives.

Researchers at Rady Children’s Hospital in San Diego are finding that rapidly sequencing the whole genomes of such babies may be key to diagnosing their conditions quicker and improving their health outcomes. Shimul Chowdhury, director of the clinical laboratory at the Rady Children’s Institute for Genomic Medicine, presented data today (October 19) on six case studies of NICU infants at the annual meeting of the American Society of Human Genetics in Orlando.  

Chowdhury and his colleagues found that for all six infants, who suffered from a variety of often exceedingly rare genetic disorders, sequencing their whole genomes led to a reduction in the length of stay in the NICU by 124 days compared to control cases and reports from the scientific literature, in which standard array or panel-based genetic testing may be used. This is likely due to the babies getting more-accurate diagnoses—and therefore more appropriate prognoses and treatment plans—sooner.

“Newborns often don’t fit traditional methods of diagnosis, as they may present with non-specific symptoms or display different signs from older children,” Chowdhury says in a statement.

In addition, the researchers calculated that rapid whole genome sequencing (rWGS) reduced the costs associated with the babies’ treatment by about $1.8 million. “The cost savings were especially striking, given that sequencing costs are still high—even with those costs, we found that rapid WGS was not just clinically useful but economically prudent,” Chowdhury added. “Given these benefits, we’d eventually like to see rapid WGS as a reimbursable first-tier test for a proportion of infants in the NICU.”

Chowdhury tells The Scientist that his group at Rady Children’s, which has performed rWGS on about 150 infants, is “in talks with multiple children’s hospitals” around the U.S. in the hopes that many more children in NICUs will have their whole genomes sequenced in the near future. 

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing